Bcr-Abl
Bcr-Abl tyrosine-kinase inhibitors (TKI) are the first-line therapy for most patients with chronic myelogenous leukemia (CML). More than 90% of CML cases are caused by a chromosomal abnormality that results in the formation of a so-called Philadelphia chromosome. This abnormality is a consequence of fusion between the Abelson (Abl) tyrosine kinase gene at chromosome 9 and the break point cluster (Bcr) gene at chromosome 22, resulting in a chimeric oncogene (Bcr-Abl) and a constitutively active Bcr-Abl tyrosine kinase that has been implicated in the pathogenesis of CML. Compounds have been developed to selectively inhibit the tyrosine kinase.
Bcr-Abl Isoform Specific Products
All Product Categories
-
Bcr-Abl Inhibitors
(201)
View all products
-
Bcr-Abl Antagonist
(1)
View all products
-
Bcr-Abl Activator
(1)
View all products
-
Bcr-Abl Modulators
(2)
View all products
-
Bcr-Abl Degraders
(24)
View all products
-
Bcr-Abl Control
(1)
View all products
-
Bcr-Abl Substrate
(1)
View all products
-
ABL1 Proteins
(7)
View all products
-
Bcr-Abl Related Products (249)
Related Products (249)
-
Recombinant Proteins (7)
-
Antibodies (6)
-
Bcr-Abl Isoform Comparison
-
ABL1 M351T Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70638The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 M351T Recombinant Human Active Protein Kinase is a recombinant ABL1 M351T protein that can be used to study ABL1 M351T-related functions.
-
PROTAC DDa-1
0 ImagesCat. No.: HY-156745CAS No.: 3036944-98-3PROTAC DDa-1 is a multi-targeted DCAF1-recruiting tyrosine kinase PROTAC degrader. PROTAC DDa-1 mediates the degradation of TNK2, CSK, LIMK2, TEC, and BTK, with a DC50 of 90 nM for BTK. PROTAC DDa-1 reduces the viability of BTK-dependent diffuse large B-cell lymphoma cells. PROTAC DDa-1 can be used for the research of diffuse large B-cell lymphoma.
-
CSF1R/c-Kit-IN-2
0 ImagesCat. No.: HY-187341CSF1R/c-Kit-IN-2 is a dual CSF-1R/c-Kit inhibitor with a c-Kit-biased profile, exhibiting inhibitory activity against CSF-1R (IC50 = 6.84 nM), c-Kit (IC50 = 0.95 nM), FYN (IC50 = 11.4 nM), ABL1 (IC50 = 14.2 nM), and CSK (IC50 = 118 nM). CSF1R/c-Kit-IN-2 can be used for the research of neuroinflammation-associated neurodegenerative diseases.
-
WB-BC-15
0 ImagesCat. No.: HY-18814CAS No.: 309760-28-9Synonyms: WGB-BC-15WB-BC-15 (WGB-BC-15) is a c-Abl kinase inhibitor. WB-BC-15 can increase radiation-induced germ-cell apoptosis, with EC50 of 10.5 μM.
-
AK-HW-90
0 ImagesCat. No.: HY-157389AK-HW-90 (compound 2B) is a potent panBcr-Abl inhibitor with significant inhibitory activity against Imatinib (HY-15463)-resistant mutants. AK-HW-90 inhibits the resistance mutant Bcr-AblT315I with an IC50 of 0.65 nM. AK-HW-90 has potential anticancer activity and can be used in the study of chronic myelogenous leukemia (CML).
-
AP24163
0 ImagesCat. No.: HY-10364CAS No.: 926922-16-9
-
BCR-ABL1-IN-2
0 ImagesCat. No.: HY-179247BCR-ABL1-IN-2 (compound 8) is a potent BCR-ABL1 tyrosine kinase inhibitor. BCR-ABL1-IN-2 exhibits activity in Imatinib (HY-15463) resistant K562/DOX cells with LC50 of 5.29 μM. BCR-ABL1-IN-2 shows no significant toxicity in nontumor cells. BCR-ABL1-IN-2 can be used for chronic myeloid leukemia research.
-
c-ABL-IN-3
0 ImagesCat. No.: HY-146528CAS No.: 2626934-64-1c-ABL-IN-3 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-3 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2021048567A1, compound 50).
-
PD173956
0 ImagesCat. No.: HY-119177CAS No.: 305820-76-2
-
AP-24567
0 ImagesCat. No.: HY-125142CAS No.: 943319-87-7AP-24567 is a Ligands for Target Protein for PROTAC, which can be used for the synthesis of SB1-G-187 (HY-137342).
-
HPK1-IN-61
0 ImagesCat. No.: HY-177272CAS No.: 875638-86-1HPK1-IN-61 (Compound 1) is an inhibitor of hematopoietic progenitor kinase 1 (HPK1) (Ki = 0.4 nM) and an inhibitor of Abl (IC50 < 0.51 nM). HPK1-IN-61 also shows inhibitory activity against LCK with an IC50 of 24 nM.
-
3'-BPANeuGc
0 ImagesCat. No.: HY-185658CAS No.: 1596134-81-43'-BPANeuGc is a high-affinity selective Siglec-G ligand. Lipid nanoparticles surface-modified with antigens and 3'-BPANeuGc inhibit BCR signal transduction. 3'-BPANeuGc is applicable to antigen-specific tolerance research.
-
GMB-805
0 ImagesCat. No.: HY-180968CAS No.: 2489876-41-5
-
Tyrphostin AG 568
0 ImagesCat. No.: HY-118964CAS No.: 151013-48-8Tyrphostin AG 568 is a tyrphostin tyrosine kinase inhibitor that induces erythroid differentiation. Tyrphostin AG 568 can be utilized in research related to autologous bone marrow transplantation.
-
BCR-ABL-IN-2
0 ImagesCat. No.: HY-18819CAS No.: 897369-18-5
-
PROTAC BCR-ABL Degrader-2
0 ImagesCat. No.: HY-180967CAS No.: 2703834-25-5PROTAC BCR-ABL Degrader-2 is a selective Bcr-AblT315 PROTAC degrader with a DC50 of 108.7 nM in Ba/F3 Bcr-AblT315I cells. PROTAC BCR-ABL Degrader-2 exhibits the most potent degradation efficacy with DR of 69.89% and 94.23% at 100 and 300 nM, respectively. PROTAC BCR-ABL Degrader-2 demonstrates high plasma exposure, and induces significant tumor regression and induces tumor cell apoptosis with a good safety profile in vivo. PROTAC BCR-ABL Degrader-2 can be used for chronic myeloid leukemia (CML) research.
-
BCR-ABL-IN-5
0 ImagesCat. No.: HY-150566CAS No.: 1795736-60-5
-
SNIPER(ABL)-047
0 ImagesCat. No.: HY-111863SNIPER(ABL)-047, conjugating HG-7-85-01 (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 2 μM.
